The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Pruritus as a Distinctive Feature of Type 2 Inflammation
Open accessAbstract
Pruritus is a common symptom of several skin diseases, both inflammatory and neoplastic. Pruritus might have a tremendous impact on patients’ quality of life and strongly interfere with sleep, social, and work activities. We review the role of type-2 inflammation and immunity in the pathogenesis of chronic pruritic conditions of the skin. Type 2 cytokines, including IL-4, IL-13, thymic stromal lymphopoietin, periostin, IL-31, IL-25, and IL-33 are released by mast cells, innate lymphoid cells 2, keratinocytes, and type 2 T lymphocytes, and are master regulators of chronic itch. These cytokines might act as direct pruritogen on primary sensory neurons (pruriceptors) or alter the sensitivity to other itch mediators Type 2 inflammation- and immunity-dominated skin diseases, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, scabies, parasitic diseases, urticaria, and Sézary syndrome are indeed conditions associated with most severe pruritus. In contrast, in other skin diseases, such as scleroderma, lupus erythematosus, hidradenitis suppurativa, and acne, type 2 inflammation is less represented, and pruritus is milder or variable. Th2 inflammation and immunity evolved to protect against parasites, and thus, the scratching response evoked by pruritus might have developed to alert about the presence and to remove parasites from the skin surface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
The immunological anatomy of the skin
Kabashima, K., Honda, T., Ginhoux, F., & Egawa, G. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0084-5 · Cited by 650
Tsoi, L. C., Rodriguez, E., Degenhardt, F., Baurecht, H., Wehkamp, U., Volks, N., Szymczak, S., Swindell, W. R., Sarkar, M. K., Raja, K., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.018 · Cited by 469
The differential expression of IL-4 and IL-13 and its impact on type-2 immunity
Bao, K., & Reinhardt, R. L. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.008 · Cited by 316
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908316 · Cited by 281 · cited 1×
“In line with a central role of Th2 cytokines, blocking the IL-4/13 or IL-31 signaling pathways, respectively, with dupilumab or nemolizumab, demonstrated short- and long-term efficacy in treating PN [87,88].”
BackgroundSelf-citation
Cited by
Jutel, M., Agache, I., Zemelka‐Wiacek, M., Akdis, M., Chivato, T., del Giacco, S., Gajdanowicz, P., Gracia, I. E., Klimek, L., Lauerma, A., et al. (2023) · Allergy · doi:10.1111/all.15889 · Cited by 295
Fania, L., Moretta, G., Antonelli, F., Scala, E., Abeni, D., Albanesi, C., & Madonna, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052684 · Cited by 128
Sofen, H., Bissonnette, R., Yosipovitch, G., Silverberg, J. I., Tyring, S., Loo, W. J., Zook, M., Lee, M., Zou, L., Jiang, G.-L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101826 · Cited by 108
Self-citationAndrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
Metadata
- Authors
- Garcovich, S., Maurelli, M., Gisondi, P., Peris, K., Yosipovitch, G., & Girolomoni, G.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-03-23
- Volume
- 9
- Issue
- 3
- Pages
- 303
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W3138228045
- Cited by
- 168
- References
- 5
- FWCI
- 20.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pruritus as a Distinctive Feature of Type 2 Inflammation. https://app.cochat.ai/papers/10.3390/vaccines9030303
- The paper
- Garcovich, S., Maurelli, M., Gisondi, P., Peris, K., Yosipovitch, G., & Girolomoni, G. (2021). Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines. https://doi.org/10.3390/vaccines9030303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.